Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy

Background: The availability of high-efficacy disease-modifying therapy (DMT), including natalizumab, improved treatment efficacy in adults with highly-active relapsing-remitting multiple sclerosis (RRMS). Natalizumab patent protection has expired, and the natalizumab biosimilar (Tyruko®) has been r...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Roberto Bergamaschi, Marco Capobianco, Roberto Ravasio
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	AboutScience Srl 2024-06-01
Cyfres:	AboutOpen
Pynciau:	Analysis Biosimilar Budget impact cost Italian NHS Natalizumab Relapsing-Remitting Multiple Sclerosis
Mynediad Ar-lein:	https://journals.aboutscience.eu/index.php/aboutopen/article/view/3078
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!